Vietnam Active Pharmaceutical Ingredient CDMO Market Growth Rate
According to 6Wresearch internal databases and industry insights, the Vietnam Active Pharmaceutical Ingredient CDMO Market is projected to grow at a CAGR of 10.84% during the forecast period 2026–2032.
Vietnam Active Pharmaceutical Ingredient CDMO Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth trajectory of the Vietnam Active Pharmaceutical Ingredient CDMO Market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The following table summarizes the historical and forecasted growth rates of the Vietnam Active Pharmaceutical Ingredient CDMO Market, along with the rationale behind each year’s performance.
| Year | Estimated Growth (%) | Market Rationale |
| 2022 | 7.3% | Recovery in pharmaceutical manufacturing following supply chain normalization. |
| 2023 | 8.1% | Growing outsourcing demand from global pharmaceutical companies. |
| 2024 | 9% | Expansion of API production facilities and foreign investment inflows. |
| 2025 | 9.8% | Higher demand for generic drug manufacturing and export-oriented production. |
| 2026 | 10.4% | Capacity expansion by domestic CDMOs and improved GMP compliance. |
| 2027 | 10.8% | Growing biologics manufacturing partnerships and technology transfer. |
| 2028 | 11.4% | Increasing demand for high-potency APIs and specialty manufacturing. |
| 2029 | 11.7% | Expansion of contract development services for innovative drug pipelines. |
| 2030 | 11.9% | Rising pharmaceutical exports supported by international certifications. |
| 2031 | 12% | Greater investment in continuous manufacturing technologies. |
| 2032 | 12.4% | Strong global outsourcing trend and higher regional API production capacity. |
Topics Covered in the Vietnam Active Pharmaceutical Ingredient CDMO Market Report
The Vietnam Active Pharmaceutical Ingredient CDMO Market Report provides an in-depth assessment based on Type and Application. It evaluates major market dynamics, technological advancements, regulatory developments, investment prospects, competitive benchmarking, and emerging opportunities while offering strategic insights into future industry growth.
Vietnam Active Pharmaceutical Ingredient CDMO Market Highlights
| Report Name | Vietnam Active Pharmaceutical Ingredient CDMO Market |
| Forecast period | 2026-2032 |
| CAGR | 10.84% |
| Growing Sector | Biologic APIs |
Vietnam Active Pharmaceutical Ingredient CDMO Market Synopsis
The Vietnam Active Pharmaceutical Ingredient CDMO Market is witnessing rapid development as pharmaceutical manufacturers increasingly outsource API development and commercial production to specialized contract organizations. API CDMOs provides end-to-end services including process development, scale-up, analytical testing, regulatory documentation, and commercial manufacturing for pharmaceutical innovators and generic drug manufacturers.
Vietnam is gradually strengthening its pharmaceutical manufacturing ecosystem through foreign direct investment, improvements in GMP-certified facilities, and supportive industrial policies aimed at reducing dependence on imported APIs. Rising demand for affordable medicines, increasing clinical development activities, and expanding export opportunities continue to position Vietnam as an emerging manufacturing destination within Southeast Asia.
Evaluation of Growth Drivers in Vietnam Active Pharmaceutical Ingredient CDMO Market (2026–2032)
Below mentioned are some major drivers and their influence on the market dynamics:
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increasing pharmaceutical outsourcing | Generic Pharmaceuticals | Global drug manufacturers continue shifting API production to cost-efficient CDMOs. |
| Expansion of GMP-certified facilities | Synthetic APIs | Improves export competitiveness and regulatory acceptance. |
| Growing biologics pipeline | Biologic APIs | Greater need for specific development and manufacturing expertise. |
| Foreign direct investment | Branded Pharmaceuticals | Promotes technology transfer and advanced manufacturing. |
| Government support for pharmaceutical localization | Generic Pharmaceuticals | Strengthens domestic API production and reduces import dependence. |
Vietnam Active Pharmaceutical Ingredient CDMO Market is projected to grow at a CAGR of 10.84% during 2026–2032 due to the trend of more pharmaceutical companies outsourcing their manufacturing process with international standards of quality system. More than 65% of the global pharmaceutical manufacturing companies outsource some of the stages in API production process, while almost 40% of the drug candidates that were recently approved use the help of CDMOs in their commercialization. Vietnam's competitiveness keeps growing due to increased manufacture in GMP standards, skilled labor, and increased investments into pharmaceutical industrial parks. Furthermore, the development of biologic drugs in the Asia-Pacific region grows by around 12% each year, providing even more chances for specialized API manufacturing.
Evaluation of Restraints in Vietnam Active Pharmaceutical Ingredient CDMO Market
Below are some major restraints and their influence on the market dynamics:
| Restraints | Primary Segment Affected | What This Means (Evidence) |
| High capital investment requirements | Biologic APIs | Advanced production facilities require significant investment. |
| Dependence on imported raw materials | Synthetic APIs | Supply disruptions increase manufacturing costs. |
| Stringent international regulatory standards | Branded Pharmaceuticals | Timely qualification reduces commercialization time. |
| Limited highly skilled biologics workforce | Biologic APIs | Highly trained specialists are still insufficient. |
| Price competition among CDMOs | Generic Pharmaceuticals | Price competition lowers the margins of operations. |
Vietnam Active Pharmaceutical Ingredient CDMO Market Challenges
The Vietnam Active Pharmaceutical Ingredient (API) CDMO Industry faces several challenges that can impact its growth and competitiveness. one of the key challenges is the lack of advanced manufacturing technology necessary for the manufacture of API, which leads to the reliance on imported technology and skills. Other challenges are related to regulatory complexity, whereby compliance with global regulations like US FDA, EMA, among others, requires significant investments in quality systems, validations, and professionals. Further, competition from other markets like India and China that have advanced manufacturing technology and larger production capacity affects overall development of this market.
Vietnam Active Pharmaceutical Ingredient CDMO Market Trends
Emerging trends shaping the Vietnam Active Pharmaceutical Ingredient CDMO Market include the following:
- Increased use of continuous manufacturing systems – Vietnam-based CDMOs are increasingly relying on continuous manufacturing systems as a means of increasing production efficiency, improving quality uniformity, minimizing waste in production processes and cutting down on costs related to API production.
- High potency API production – The increase in demand for oncology and targeted therapies is driving increased focus on high potency API (HPAPI) production.
- International partnerships – More collaboration between pharmaceutical companies worldwide and Vietnam manufacturers will increase expertise and make Vietnam a viable market for API outsourcing.
Investment Opportunities in the Vietnam Active Pharmaceutical Ingredient CDMO Market
Key areas of investment potential in the Vietnam Active Pharmaceutical Ingredient CDMO Market are outlined below:
- Biologic manufacturing infrastructure – Expanding biologics pipelines and rising demand for advanced therapies are creating significant investment opportunities in biologic API facilities, including cell culture, purification, and specialized manufacturing infrastructure.
- Process development laboratories for APIs – Growing pharmaceutical outsourcing activities are increasing demand for advanced process development, analytical testing, and optimization laboratories that support API scale-up, validation, and commercial manufacturing activities.
- Green pharmaceutical manufacturing – Investments in sustainable manufacturing practices, energy-efficient technologies, waste reduction systems, and environmentally friendly production processes are gaining importance as companies aim to improve operational efficiency and strengthen export competitiveness.
Top Players in Vietnam Active Pharmaceutical Ingredient CDMO Market
Below is an overview of key companies operating in the Vietnam Active Pharmaceutical Ingredient CDMO Market:
1. Mekophar Chemical Pharmaceutical Joint Stock Company (Mekophar)
| Company Name | Mekophar Chemical Pharmaceutical Joint Stock Company (Mekophar) |
|---|---|
| Established Year | 1975 |
| Headquarters | Ho Chi Minh City, Vietnam |
| Official Website | Click Here |
Mekophar is one of Vietnam’s leading pharmaceutical manufacturers, with activities spanning pharmaceuticals, pharmaceutical raw materials, chemicals, medical devices, and related healthcare products.
2. Imexpharm Corporation
| Company Name | Imexpharm Corporation |
|---|---|
| Established Year | 1977 |
| Headquarters | Dong Thap, Vietnam |
| Official Website | Click Here |
Imexpharm is a major Vietnamese pharmaceutical manufacturer operating multiple production facilities, including facilities meeting EU-GMP standards, and focuses on high-quality pharmaceutical production.
3. DHG Pharmaceutical Joint Stock Company (DHG Pharma)
| Company Name | DHG Pharmaceutical Joint Stock Company (DHG Pharma) |
|---|---|
| Established Year | 1974 |
| Headquarters | Can Tho, Vietnam |
| Official Website | Click Here |
DHG Pharma is a major Vietnamese pharmaceutical company offering pharmaceutical products supported by modern manufacturing capabilities and quality management systems.
4. Traphaco Joint Stock Company
| Company Name | Traphaco Joint Stock Company |
|---|---|
| Established Year | 1972 |
| Headquarters | Hanoi, Vietnam |
| Official Website | Click Here |
Traphaco is a leading Vietnamese pharmaceutical company with more than five decades of development, combining traditional medicine expertise with modern technology and pharmaceutical manufacturing capabilities.
5. Medochemie
| Company Name | Medochemie |
|---|---|
| Established Year | 1976 |
| Headquarters | Ho Chi Minh City, Vietnam |
| Official Website | Click Here |
Medochemie was established in Cyprus in 1976 and operates five manufacturing plants in Vietnam as part of its international pharmaceutical manufacturing network.
Government Initiatives being implemented in the Vietnam Active Pharmaceutical Ingredient CDMO Market
The Vietnamese government continues promoting pharmaceutical manufacturing through the National Strategy for Pharmaceutical Industry Development to 2030 with Vision to 2045, which encourages domestic API production and greater self-sufficiency. Incentives for high-tech manufacturing, industrial park development, and foreign investment have strengthened pharmaceutical production capacity. Vietnam also continues aligning GMP standards with international guidelines while promoting technology transfer through public-private partnerships. Programs supporting research collaboration between universities and pharmaceutical manufacturers further contribute to improving local manufacturing capabilities.
Future Insights of the Vietnam Active Pharmaceutical Ingredient CDMO Market
The Vietnam Active Pharmaceutical Ingredient (API) CDMO Industry is expected to witness significant growth in the coming years, driven by increasing pharmaceutical outsourcing activities, rising demand for cost-effective manufacturing solutions, and the expansion of Vietnam’s pharmaceutical industry.
As global pharmaceutical companies seek alternative manufacturing destinations to diversify supply chains and reduce dependence on traditional API manufacturing hubs, Vietnam is emerging as an attractive location due to its competitive labor costs, improving regulatory framework, strategic geographic position, and growing manufacturing capabilities.
The market is likely to benefit from increasing investments in GMP-compliant facilities, advanced API production technologies, and specialized manufacturing capabilities for complex molecules.
Market Segmentation Analysis
This report presents a detailed analysis of the market segments along with their leading categories.
By Type – Synthetic APIs Dominate the Market while Biologic APIs Register the Fastest Growth
According to Bhawna Singh, Assistant Manager, 6Wresearch, Synthetic APIs accounted for approximately 76.20% of the Vietnam active pharmaceutical ingredient CDMO market share in 2025, supported by their widespread utilization in generic medicines, mature manufacturing technologies, lower production costs, and strong global outsourcing demand. Meanwhile, Biologic APIs are projected to register the highest CAGR of 13.42% during 2026–2032, driven by increasing biosimilar development, expanding biologic drug pipelines, and growing investments in advanced biopharmaceutical manufacturing infrastructure.
By Application – Generic Pharmaceuticals Lead the Market while Branded Pharmaceuticals Experience Strong Growth
Generic Pharmaceuticals held nearly 61.80% of the market share in 2025, owing to increasing demand for affordable medicines, expanding export production, and higher outsourcing volumes from multinational pharmaceutical companies. On the other hand, the branded pharmaceuticals are anticipated to grow at a CAGR of 11.71% during 2026–2032, supported by rising innovative drug development, increasing technology transfer partnerships, and greater investment in high-value API manufacturing.
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
Key Attractiveness of the Report:
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year: 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- Vietnam Active Pharmaceutical Ingredient CDMO Market Outlook
- Market Size of Vietnam Active Pharmaceutical Ingredient CDMO Market, 2025
- Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market, 2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Revenues & Volume for the Period 2022-2032
- Vietnam Active Pharmaceutical Ingredient CDMO Market Trend Evolution
- Vietnam Active Pharmaceutical Ingredient CDMO Market Drivers and Challenges
- Vietnam Active Pharmaceutical Ingredient CDMO Price Trends
- Vietnam Active Pharmaceutical Ingredient CDMO Porter's Five Forces
- Vietnam Active Pharmaceutical Ingredient CDMO Industry Life Cycle
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Type for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Synthetic APIs for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Biologic APIs for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Application for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Generic Pharmaceuticals for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Branded Pharmaceuticals for the Period 2022-2032
- Historical Data and Forecast of Vietnam Active Pharmaceutical Ingredient CDMO Market Revenues & Volume By Over-the-Counter (OTC) Medications for the Period 2022-2032
- Vietnam Active Pharmaceutical Ingredient CDMO Import Export Trade Statistics
- Market Opportunity Assessment By Type
- Market Opportunity Assessment By Application
- Vietnam Active Pharmaceutical Ingredient CDMO Top Companies Market Share
- Vietnam Active Pharmaceutical Ingredient CDMO Competitive Benchmarking By Technical and Operational Parameters
- Vietnam Active Pharmaceutical Ingredient CDMO Company Profiles
- Vietnam Active Pharmaceutical Ingredient CDMO Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments:
By Type
- Synthetic APIs
- Biologic APIs
By Application
- Generic Pharmaceuticals
- Branded Pharmaceuticals
- Over-the-Counter (OTC) Medications
